The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor (PPAR) delta (δ) agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from patients with mitochondrial complex I deficiency” at the following upcoming scientific meetings.

PittGene Meeting
Date: Wednesday, October 25, 2023, at 2:00-2:45pm ET
Location: University Club at University of Pittsburgh, Pittsburgh, PA
Presenter: Bianca Seminotti, PhD

Translational Research in Mitochondria, Metabolism, Aging and Disease (TRiMAD) Meeting 2023
Date: Monday, November 6, 2023, at 5:30-7:00pm ET
Location: University Club at University of Pittsburgh, Pittsburgh, PA
Presenter: Bianca Seminotti, PhD

In this presentation, Reneo and collaborators will report findings which demonstrate that the bioenergetic deficiencies and mitochondrial dysfunction observed in CI-deficient patient fibroblasts can potentially be alleviated by treatment with mavodelpar, a potent and selective PPARδ agonist. Furthermore, because mavodelpar activation results in increased transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation and energy production in the form of ATP, these results provide mechanistic evidence for the potential of mavodelpar as a therapeutic option in this and similar types of primary mitochondrial myopathies (PMM).

Mavodelpar is an investigational drug product candidate that is under clinical investigation, and which has not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, or any other regulatory agency.

About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler 
Investor Relations 
Reneo Pharmaceuticals, Inc. 
dspangler@reneopharma.com

Matthew Purcell, Pharm.D.
Media Inquiries 
Russo Partners, LLC 
matthew.purcell@russopartnersllc.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.